RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
…
Rockwood Research

Corporate filings · Event Monitor · Free for all

← Back

SAB Biotherapeutics, Inc.

SABS

Biological Products, (No Diagnostic Substances) · SIC 2836 · CIK 0001833214

SHARE:XLINKEDINEMAIL
Revenue FY2025
$0.0M
Net Income
$13.0M
EPS (Basic)
$0.22
Net Margin
—
ROE
8.8%
Total Equity
$151.0M
Shares Out
91M

SAB Biotherapeutics, Inc. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2020–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Revenue & Net Income (10Y)

Margin Trends

Investor Ownership · 3 funds in our universe

FundPosition Value% of AUMQoQ ChgWeight
Vivo Capital
Vivo Capital
$28.5M
0.5%
(36.1%)
RA Capital Management
RA Capital Management
$17.2M
0.1%
—
Adage Capital Management
Adage Capital Management
$25.0M
0.0%
+88.1%

Insider Transactions

Reading stored insider transactions…